History of Research on Tumor Angiogenesis

Focusing on the groundbreaking hypothesis by J. Folkman in 1971 regarding the dependence of tumor growth on angiogenesis, this book explores the evolution of this concept leading to the FDA's approval of the first angiogenesis inhibitor in 2004. It compiles significant literature that highlights the antiangiogenic strategies in cancer treatment, providing insights into the scientific advancements and implications for future therapies in oncology.